These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Velaxin (venlafaxine) in the treatment of anxious depression].
    Author: Il'ina NA.
    Journal: Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):24-8. PubMed ID: 18427537.
    Abstract:
    Thirty patients (7 male, 23 female) mean age 35,3+/-7,8 years with anxious or anxious-apathic depression, including 24 in-patients and 6 out-patients. They were treated during 8 weeks with velaxin in dosage 225-375 mg per day. The changes of patient state evaluated with rating scales (CGI, HDRS, BDI, HADS-21). Twenty-seven patients (90%) completely underwent the course of treatment. Responders according to CGI were 25 (83,3%) cases: "improvement" - 16 (59,3%), "apparent improvement" - 9 (33,3%); "minor improvement" - 2 (7,4%) patients. The complete reduction of depressive symptoms was recorded in 33,3% of cases. The safety of velaxin in moderate therapeutic doses as well as improvement of laboratory and instrumental characteristics of somatic state was confirmed.
    [Abstract] [Full Text] [Related] [New Search]